In the study by Krejcik et al., daratumumab activated and expanded cytotoxic T-cells and decreased CD38-expressing immunosuppressive regulatory T and B cells in patients with multiple myeloma (Krejcik et al., 2016). Here, CD38 is linked to plasma cell myeloma.